MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Disclosure Management

Originally Published MX September/October 2003

Government & Legal Affairs

Return to article:

Start Spreading
the News?

To avoid premature, overoptimistic, or other problematic disclosure of potentially false or misleading information emerging from clinical studies, medtech company executives should:

o Restrict access to sensitive information to only those who need to know.
o Make public announcements only when products are in late stages of clinical development.
o Create a written corporate disclosure policy.
o Train employees to observe the policy.
o Consult FDA whenever in doubt. 

Copyright ©2003 MX

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish